Cited 2 times in
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.date.accessioned | 2024-01-03T00:23:11Z | - |
dc.date.available | 2024-01-03T00:23:11Z | - |
dc.date.issued | 2023-08 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197253 | - |
dc.description.abstract | Background: ONO-4538-52/TASUKI-52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first-line) treatment of patients with advanced non-squamous non-small cell lung cancer (nsNSCLC). At the interim analysis (minimum follow-up, 7.4 months), the independent radiology review committee-assessed progression-free survival was significantly longer in the nivolumab arm, but overall survival (OS) data were immature. Methods: Here, we present the updated OS data. Patients with treatment-naïve stage IIIB/IV or recurrent nsNSCLC without driver mutations in ALK, EGFR, or ROS1, were randomized 1:1 to receive either nivolumab or placebo. Patients in both arms received paclitaxel, carboplatin, and bevacizumab, administered 3-weekly for a maximum of 6 cycles. Nivolumab/placebo and bevacizumab were subsequently continued until disease progression or unacceptable toxicity. Results: Overall, 550 patients were randomized. At the time of the analysis (minimum follow-up: 19.4 months), the median OS was longer in the nivolumab arm than in the placebo arm (30.8 vs. 24.7 months; hazard ratio 0.74, 95% confidence interval 0.58-0.94). The 12-month OS rates were 81.3% vs. 76.3% in the nivolumab vs. placebo arms, respectively. The respective 18-month OS rates were 69.0% vs. 61.9%. Conclusion: Nivolumab plus platinum chemotherapy and bevacizumab demonstrated longer OS vs. the placebo combination. We believe this regimen is viable as a standard, first-line treatment for patients with advanced nsNSCLC without driver mutations in ALK, EGFR, or ROS1. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | John Wiley & Sons Ltd. | - |
dc.relation.isPartOf | CANCER MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Bevacizumab / adverse effects | - |
dc.subject.MESH | Carboplatin / adverse effects | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / drug therapy | - |
dc.subject.MESH | ErbB Receptors | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms* / drug therapy | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Nivolumab / adverse effects | - |
dc.subject.MESH | Paclitaxel / adverse effects | - |
dc.subject.MESH | Platinum | - |
dc.subject.MESH | Protein-Tyrosine Kinases | - |
dc.subject.MESH | Proto-Oncogene Proteins | - |
dc.subject.MESH | Receptor Protein-Tyrosine Kinases | - |
dc.subject.MESH | Survival Analysis | - |
dc.title | First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Shunichi Sugawara | - |
dc.contributor.googleauthor | Jong-Seok Lee | - |
dc.contributor.googleauthor | Jin-Hyoung Kang | - |
dc.contributor.googleauthor | Naoki Inui | - |
dc.contributor.googleauthor | Toyoaki Hida | - |
dc.contributor.googleauthor | Ki Hyeong Lee | - |
dc.contributor.googleauthor | Tatsuya Yoshida | - |
dc.contributor.googleauthor | Hiroshi Tanaka | - |
dc.contributor.googleauthor | Cheng-Ta Yang | - |
dc.contributor.googleauthor | Makoto Nishio | - |
dc.contributor.googleauthor | Yuichiro Ohe | - |
dc.contributor.googleauthor | Tomohide Tamura | - |
dc.contributor.googleauthor | Nobuyuki Yamamoto | - |
dc.contributor.googleauthor | Chong-Jen Yu | - |
dc.contributor.googleauthor | Hiroaki Akamatsu | - |
dc.contributor.googleauthor | Shigeru Takahashi | - |
dc.contributor.googleauthor | Kazuhiko Nakagawa | - |
dc.identifier.doi | 10.1002/cam4.6348 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J00449 | - |
dc.identifier.eissn | 2045-7634 | - |
dc.identifier.pmid | 37641544 | - |
dc.subject.keyword | bevacizumab | - |
dc.subject.keyword | chemotherapy | - |
dc.subject.keyword | nivolumab | - |
dc.subject.keyword | non-squamous non-small cell lung cancer | - |
dc.subject.keyword | survival | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.citation.volume | 12 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 17061 | - |
dc.citation.endPage | 17067 | - |
dc.identifier.bibliographicCitation | CANCER MEDICINE, Vol.12(16) : 17061-17067, 2023-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.